- Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
Upturn AI Summary - About
CareDx Inc(CDNA)
Advisory History & Simulated Performance *
*as per simulation (see disclosures)- ALL
- 1Y
- 1M
- 1W
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- PASS (Skip)
Advisory Performance History (Simulated)
Upturn Advisory & Investor View for CDNA
11/16/2026: CDNA (4-star) is a SELL. SELL for 2 days. Simulated Profits (265.81%). Updated daily EoD!
CareDx Inc is a precision medicine diagnostics stock focused on non-invasive post-transplant monitoring and specialty oncology. The company's main strengths lie in its flagship molecular tests like AlloSure and its expanding profit margins supported by strong clinical adoption. Its primary growth opportunity stems from scaling new oncology offerings like NavDx and advancing pipeline programs into cell therapy. Key risks include intense competition from larger molecular diagnostics players and potential shifts in healthcare reimbursement policies. The stock best suits growth-oriented investors willing to monitor regulatory updates, reimbursement trends, and pipeline commercial execution.
How to Read the Upturn Advisory
The Upturn Star Rating and the current BUY, SELL, or PASS advisory are generated by Upturn’s AI advisory engine based on proprietary signal analysis, price behavior, advisory history, and historical signal performance.
Company fundamentals, valuation, risks, and news provide supporting context about the business.
Investor Fit
| Investor style | Fit | Why |
|---|---|---|
| Growth investor | Strong fit | CareDx exhibits high double-digit revenue growth and expanding market opportunities in precision diagnostics. |
| Momentum investor | Strong fit while signal remains positive | Recent earnings beats and upward earnings revisions support positive technical momentum when market upturn signals persist. |
| Value investor | Mixed fit | Trading at elevated growth multiples makes it less suitable for traditional deep-value strategies. |
| Dividend investor | Weak fit | The company does not pay dividends, focusing entirely on capital appreciation and business expansion. |
| Low-risk investor | Weak fit | Healthcare regulatory risks, litigation exposure, and stock price volatility present higher risk profiles. |
Risk Profile
| Risk factor | Level | Why it matters |
|---|---|---|
| Price volatility | High | Biotech and diagnostics stocks frequently experience sharp swings based on clinical updates or earnings reports. |
| Valuation risk | Medium / high | Higher earnings multiples require sustained execution to justify current valuation levels. |
| Competition risk (Natera and molecular diagnostics peers) | High | Intense rivalry in non-invasive testing can pressure market share and test pricing. |
| Business quality | Medium / high | Proprietary testing technologies provide high gross margins and strong clinical moats. |
| Dividend income | Low / none | No dividend payout is provided for income-seeking investors. |
| Execution risk | Medium | Successful commercial rollout of new pipeline diagnostics like AlloHeme is critical for future growth. |
Key Highlights
Company Size Mid-Cap Stock | Market Capitalization 4.09B USD | Price to earnings Ratio 32.86 | 1Y Target Price 94.43 |
Price to earnings Ratio 32.86 | 1Y Target Price 94.43 | ||
Volume (30-day avg) 1.4M shares | Beta 2.49 | 52 Weeks Range 15.22 - 90.87 | Updated Date 11/15/2026 |
52 Weeks Range 15.22 - 90.87 | Updated Date 11/15/2026 | ||
Dividends yield (FY) - | Basic EPS (TTM) 2.37 |
Sector & Industry Intelligence
Sector
Healthcare
Bullish- Sentiment
- Strong Bullish
- Momentum
- Momentum Steady
- BUY participation
- 63.9%
- Active BUY / eligible
- 69 / 108
- 30-Day BUY Count Change
- +31
- Market state
- Strong Bullish
The number of qualifying BUY stocks has remained relatively stable.
Industry
Diagnostics & Research
- BUY participation
- 61.5%
- Active BUY / eligible
- 8 / 13
- 30-Day BUY Count Change
- -1
Sector signal summarizes BUY breadth conditions for the sector. It does not override this stock’s BUY, SELL, or PASS advisory.
Price Behavior

Strong Uptrend
The stock has maintained a strong upward price trend across the last three quarters.

Extreme Price Shocks
The stock has experienced exceptionally large and disruptive price movements during the period.
Analysis of Past Performance
Type Stock | Historic Profit 162.36% | Avg. Invested days 51 | Today’s Advisory SELL |
Upturn Advisory Rating ![]() | Upturn Advisory Performance | Stock Returns Performance |
Upturn Scorecard
Upturn Star Rating 
Company Fundamentals 
Financial Health Rating 
Growth Momentum Score 
Ownership 
Top 5 Institutional Investors
Unit Economics (Per $1K Revenue) 
Economic Dimensions
Quantitative Style Profile 
Style Classification
Quality Focused
How Company Makes Money
| Business area | What it includes | Retail investor read |
|---|---|---|
| Testing Services | Commercial laboratory testing fees for AlloSure, AlloMap, and NavDx diagnostics. | This is the primary engine driving the vast majority of company revenues. |
| Patient and Digital Solutions | CareDx Pharmacy services, digital health tools, and patient support infrastructure. | Provides supplementary high-margin recurring engagement across transplant workflows. |
| Geographic Exposure | Primarily the United States healthcare market. | The business is centrally concentrated on domestic hospital and transplant center networks. |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Product revenue - Year on Year
Revenue by Geography
Geography revenue - Year on Year
Earnings Date
Report Date 2026-10-29 | When After Market | Estimate 0.07 | Actual 0.7 |
Profitability
Profit Margin 25.86% | Operating Margin (TTM) 1.57% |
Management Effectiveness
Return on Assets (TTM) 0.91% | Return on Equity (TTM) 33.04% |
Valuation
Trailing PE 32.86 | Forward PE 68.49 | Enterprise Value 3.87B | Price to Sales(TTM) 8.23 |
Enterprise Value 3.87B | Price to Sales(TTM) 8.23 | ||
Enterprise Value to Revenue 7.78 | Enterprise Value to EBITDA 139.16 | Shares Outstanding 52.54M | Shares Floating 50.80M |
Shares Outstanding 52.54M | Shares Floating 50.80M | ||
Percent Insiders 3.21 | Percent Institutions 102.32 |
Financial Metrics
🧭 Investment Snapshot
Total Revenue (Scale)
Total money earned from selling products or services before any costs. It is needed to understand the scale of the business and its ability to generate income.
Net Income (Profit)
Final profit after all expenses, interest, and taxes are deducted. It is needed to determine the overall profitability available to shareholders.
Free Cash Flow (Cash Strength)
Cash remaining after operating activities and capital expenditures, showing cash available for growth. It is needed to evaluate the company’s ability to invest, pay dividends, or reduce debt.
📈 Growth & Strength
Operating Income (Core Profit)
Profit from core operations after deducting all operating expenses. It is needed to measure how efficiently the company runs its primary business activities.
EBITDA (Cash Earnings)
Earnings before interest, taxes, depreciation, and amortization, indicating operating cash potential. It is needed to compare operating performance across companies without accounting or financing differences.
Gross Profit (Unit Profitability)
Revenue minus cost of revenue, showing profit after direct production costs. It is needed to evaluate core business profitability before overhead expenses.
🛡️ Financial Safety
Cash (Liquidity Buffer)
Total cash and cash equivalents on hand. It is needed to evaluate immediate liquidity and financial flexibility.
Total Debt (Leverage Risk)
Total debt including both short-term and long-term components. It is needed to assess the company’s leverage and financial risk.
Net Working Capital (Short-Term Health)
Current assets minus current liabilities, indicating short-term liquidity strength. It is needed to assess whether the company can meet its short-term obligations.
🧱 Balance Sheet Strength
Stockholder Equity (Net Worth)
Total equity value held by shareholders. It is needed to understand the net worth of the company from the owners’ perspective.
Total Assets (Asset Base)
The full value of everything the company owns, including cash, inventory, equipment, and investments. It is needed to understand the resource base used to generate revenue.
Income Before Tax (Pre-Tax Earnings)
Income before provision for income taxes. It is needed to analyze profitability independent of tax structures.
⚙️ Cost & Drag Factors
Cost of Revenue (Production Cost)
Direct costs required to produce and deliver the products or services sold. It is needed to assess efficiency in production and service delivery.
Total Operating Expenses (Operating Cost)
Indirect costs of running the business such as salaries, marketing, and administration. It is needed to understand how much it costs to sustain ongoing business operations.
Income Tax Expense (Tax Drag)
Amount of taxes paid or payable to the government. It is needed to evaluate the impact of taxation on overall profitability.

Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.
All company names, trademarks, logos, and brands are the property of their respective owners and are used for identification and informational purposes only. Use of these names, trademarks, and logos does not imply endorsement by their respective owners.

